Zhaolong Pharmaceutical

Zhaolong Pharmaceutical is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics targeting G protein-coupled receptors (GPCRs). The company leverages its proprietary structure-based drug discovery platform to design highly selective modulators for traditionally challenging GPCR targets involved in oncology and immunology. Its lead program, ZL-82, is a potent and selective CXCR2 antagonist currently being evaluated in clinical trials for solid tumors and chronic obstructive pulmonary disease. Zhaolong is managed by an experienced team of industry veterans with a track record in global pharmaceutical R&D. The company is committed to delivering first-in-class or best-in-class treatments to address significant unmet medical needs in chronic inflammatory and malignant diseases.